Podcast
MSL Talk: Tom Caravela, Josh Corriveau
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Summary
Precision oncology relies upon genomic sequencing of a patient’s tumor to determine optimal treatment. Precision therapies typically target genetic aberrations within cancer, and this approach has widespread enthusiasm driven by high response rates. Often, genomically-targeted drugs gain Food and Drug Administration (FDA) approval in single-arm trials that lack a comparator group. As such, response rates, which measure the percentage of patients who have tumor shrinkage beyond the RECIST 1.1 cut-off of 30%, are often used as a study endpoint.
Prior studies have evaluated the percentage of US cancer patients with advanced or metastatic cancer who are eligible for and respond to this class of medications. Specifically, genome-targeted therapy was found to apply to 8.3% of US cancer patients as of 2018, and 4.9% might experience a partial or complete response. However, since that publication, the number of FDA approvals for drugs targeting genetic indications has grown rapidly. We therefore sought to update the estimates of both eligibility for and response to genome-targeted and genome-informed therapies for drugs that have been FDA-approved to reflect estimates as of 2020.
genome-targeted therapy, eligibility, response
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Josh Corriveau
Article
Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Article
Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
P.S. Mishra-Kalyani, L. Amiri Kordestani, D.R. Rivera, H. Singh, A. Ibrahim, R.A. DeClaro, Y. Shen, S. Tang, R. Sridhara, P.G. Kluetz, J. Concato, R. Pazdur, J.A. Beaver
External control arms in oncology: current use and future directions
Article
Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles